Low-grade (LG) serous ovarian carcinoma is believed to arise from serous borderline ovarian tumors; yet the progression from serous borderline tumors to LG serous ovarian carcinoma remains poorly understood. The purpose of this study was to identify differentially expressed genes between the 2 groups. Expression profiles were generated from 6 human ovarian surface epithelia, 8 serous borderline ovarian tumors (SBOTs), 13 LG serous ovarian carcinomas, and 24 high-grade (HG) serous ovarian carcinomas. The anterior gradient homolog 3 (AGR3) gene was found to be highly upregulated in serous borderline ovarian tumors. This finding was validated by realtime quantitative reverse-transcription polymerase chain reaction, Western blotting, and immunohistochemistry. Anti-AGR3 immunohistochemistry was performed on an additional 56 LG and 103 HG tissues, and the results were correlated with clinical data. Expression profiling determined that 1254 genes were differentially expressed (P<0.005) among SBOT, LG, and HG tumors. SBOTs exhibited robust positive staining for AGR3, with a lower percentage of tumor cells stained in LG and HG. Immunofluorescence staining indicated that AGR3 expression was limited to ciliated cells. Tumor samples with a high percentage (>10%) of AGR3 positively stained tumor cells were associated with improved longer median survival in both the LG (P = 0.013) and HG (P = 0.008) serous ovarian carcinoma groups. The progression of SBOT to LG serous ovarian carcinoma may involve the dedifferentiation of ciliated cells. AGR3 could serve as a prognostic marker for survival in patients with LG and HG serous ovarian carcinomas. (Am J Surg Pathol 2011;35:904-912)
Abstract: Low-grade (LG) serous ovarian carcinoma is believed to arise from serous borderline ovarian tumors; yet the progression from serous borderline tumors to LG serous ovarian carcinoma remains poorly understood. The purpose of this study was to identify differentially expressed genes between the 2 groups. Expression profiles were generated from 6 human ovarian surface epithelia, 8 serous borderline ovarian tumors (SBOTs), 13 LG serous ovarian carcinomas, and 24 high-grade (HG) serous ovarian carcinomas. The anterior gradient homolog 3 (AGR3) gene was found to be highly upregulated in serous borderline ovarian tumors. This finding was validated by realtime quantitative reverse-transcription polymerase chain reaction, Western blotting, and immunohistochemistry. Anti-AGR3 immunohistochemistry was performed on an additional 56 LG and 103 HG tissues, and the results were correlated with clinical data. Expression profiling determined that 1254 genes were differentially expressed (P<0.005) among SBOT, LG, and HG tumors. SBOTs exhibited robust positive staining for AGR3, with a lower percentage of tumor cells stained in LG and HG. Immunofluorescence staining indicated that AGR3 expression was limited to ciliated cells. Tumor samples with a high percentage (>10%) of AGR3 positively stained tumor cells were associated with improved longer median survival in both the LG (P = 0.013) and HG (P = 0.008) serous ovarian carcinoma groups. The progression of SBOT to LG serous ovarian carcinoma may involve the dedifferentiation of ciliated cells. AGR3 could serve as a prognostic marker for survival in patients with LG and HG serous ovarian carcinomas. O varian cancer is the most lethal gynecologic cancer in the United States, causing approximately 13,850 deaths per year. 7 Among the different histologic subtypes, serous ovarian carcinoma (SOC) is the most common; yet its etiology remains unclear. Our previous study has shown that the gene expression profiles of serous borderline ovarian tumors (SBOT) are more closely related to those of low-grade (LG) SOC than to those of high-grade (HG) SOC. 2, 26 The concept that SBOT progresses to LG SOC, whereas HG SOC likely develops from an unidentified precursor, is also gaining acceptance. 2, 12, [19] [20] [21] 23, 24, 28 Nevertheless, the progression from SBOT to LG SOC remains poorly understood.
To better understand the progression from SBOT to LG SOC and validate that HG and LG SOCs are molecularly distinct entities, we compared the gene expression profiles of these groups and identified a list of differentially expressed genes. This list included one particular gene of interest, the anterior gradient homolog 3 (AGR3) gene, which has been implicated in breast cancer. AGR3 [or breast cancer membrane protein 11 (BCMP11)] was originally identified as a membrane protein from breast cancer cell lines using a proteomic approach. 1 AGR3 contains putative CXXS Tx-domain motifs, and has been implicated in the growth and metastasis of hormone-responsive breast tumors. 1, 4 Here, we report for the first time the differential expression of AGR3 in ovarian cancer, and evaluate its expression in serous ovarian cancer. We also correlate its expression with patient survival.
MATERIALS AND METHODS

Tissue Samples
Paraffin-embedded sections from patients with SBOT, advanced-stage LG SOC, and advanced-stage HG SOC were obtained from the archives of the Department of Pathology at The University of Texas MD Anderson Cancer Center (Houston, TX). All cases were reviewed and classified as LG or HG by gynecologic pathologists (A.M. and M.T.D.) using histologic criteria described previously. 13, 14 Frozen tissues were obtained from the Multidisciplinary Gynecologic Cancer Translational Research Tissue Bank at the MD Anderson Cancer Center, and all cases were validated by morphologic review at the time of retrieval. All tissue specimens had been collected and archived previously under protocols approved by the institutional review board.
Gene Expression Profiling and Data Analysis
Expression profiles were extracted from 6 human ovarian surface epithelia (HOSE), 8 SBOTs, 13 LG SOCs, and 24 HG SOCs, and profiles were then generated with a commercial GeneChip Human Genome U133 Plus 2.0 Array (all from Affymetrix except where noted otherwise). To successfully generate a sufficient amount of labeled complementary ribonucleic acid (cRNA) for microarray analysis from 25 ng total RNA, 2 rounds of amplification were necessary and were achieved with the 2-Cycle cDNA Synthesis Kit. For the first round of synthesis of doublestranded cDNA, total RNA was reverse transcribed using the oligo(dT)24-T7 (5 0 -GGCCAGTGAATTGTAATAC GACTCACTATAGGGAGGCGG-3 0 ) primer according to the instructions of the manufacturer, followed by amplification with the MEGAscript T7 Kit (Ambion, Inc.). After cleanup of the cRNA with a GeneChip Sample Cleanup Module, second-round double-stranded cDNA was amplified using the Gene Chip IVT Labeling Kit. A 15.0 mg aliquot of labeled product was fragmented by heat-mediated and ion-mediated hydrolysis at 941C for 35 minutes in 24 mL H 2 O and 6 mL of 5 Â fragmentation buffer. The fragmented cRNA was hybridized for 16 hours at 451C in a Hybridization Oven 640 to a GeneChip Human Genome U133 Plus 2.0 oligonucleotide array. Washing and staining the arrays with phycoerythrinconjugated streptavidin (Molecular Probes) was completed in a GeneChip Fluidics Station 450. The arrays were then scanned using a confocal laser GeneChip Scanner 3000 and GeneChip operating software.
Real-time Quantitative Reverse-transcription Polymerase Chain Reaction (RT-PCR)
Total RNA extraction (RNeasy Mini Kit, Qiagen) and cDNA synthesis (High-Capacity cDNA Archive Kit, Applied Biosystems) were performed according to the instructions of the manufacturer. Total RNA was extracted from 51 microdissected samples (6 HOSE, 8 SBOT, 13 LG, and 24 HG serous ovarian tumors). Real-time RT-PCR was performed twice in triplicate using TaqMan primer sets for AGR3 and the housekeeping gene cyclophilin (Applied Biosystems). All reactions were run in a 7300 Real Time PCR System (Applied Biosystems). The amount of change (as a percentage) was calculated with the DDCt method as described previously. 25 
Immunohistochemistry
The AGR3 polyclonal antibody was raised in rabbits immunized with 2 specific peptides, CAQNEEI QEMAQNKFIMLNLMHET and CTYEPRDLPL LIENMKKALRLIQSEL, as described previously. 1 Custom antibodies were obtained from 21st Century Biochemicals. Paraffin sections (4 mm thick) were cut from formalin-fixed paraffin-embedded specimens, and were then placed on glass slides. Before staining, the paraffinembedded tissue sections were incubated at 601C overnight to improve adherence to the slide. At room temperature, the specimens were deparaffinized in xylene and rehydrated through 100%, 95%, and 75% ethanol and dH 2 O. Antigen retrieval was then performed in 1 Â Reveal (Biocare Medical) in a Decloaking Chamber (Biocare Medical) heated at 1201C for 15 minutes. The cooled slides were washed with dH 2 O and 1 Â Immunocare tris buffered saline (TBS) (Biocare Medical), each for 5 minutes. Background SNIPER (Biocare Medical) was applied for 20 minutes to reduce nonspecific background staining, and TBS-rinsed sections were then incubated at a dilution of 1:250 in 1% fresh bovine serum albumin buffer for 120 minutes. To remove unbound antibodies, the slides were washed twice in TBS buffer for 10 minutes. The slides were then incubated with Mach3 rabbit IgG probe (Biocare Medical) and then with Mach3 polymer alkaline-phosphatase (Biocare Medical); after each treatment, the slides were washed twice with TBS buffer for 10 minutes. Vulcan Fast Red (Biocare Medical) was applied for 10 minutes, and the slides were then rinsed with dH 2 O, counterstained with Vector Hematoxylin QS (Vector Laboratories), and were rinsed again. The slides were fixed with a Permount Mounting Medium (Fisher Scientific) and evaluated by light microscopy at 10X and 20X, with photography at 20X documenting staining intensity.
As the staining of the AGR3 polyclonal antibody was particularly robust, staining was classified according to percentages of cells staining positively (0,<10%, 10% to 25%, 25% to 50%, 50% to 75%, and >75%). Intestinal and fallopian tube tissues served as positive controls, and 17 SBOT slides were stained. For the survival analysis, 159 slides were stained (56 LG and 103 HG specimens). As the percentage of AGR3-positive staining in HG SOCs was very low, a subset of 30 HG slides containing specimens from patients at the survival extremes ( <20 mo, >90 mo) was selected initially and stained. As the initial correlation between positive staining and survival time was positive, an additional 73 slides from randomly selected patients with various survival times were examined. The slides were reviewed and divided into high (>10%) and low ( <10%) staining intensity categories. Clinical data were collected on survival time (from diagnosis to death), International Federation of Gynecology and Obstetrics stage, and tumor cytoreduction status (defined as <2 cm of residual disease at the completion of tumor-reductive surgery).
Western Blot Analysis
Total protein lysates from 5 SBOT, 7 LG, and 6 HG tissues, which were different from the set of 51 tumor samples used for expression analysis, were extracted for Western blot analysis. Tumor tissues were homogenized and subjected to radioimmunoprecipitation (RIPA) buffer to extract protein lysates. Sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) was performed using protein lysates (10 mg) on a 10% SDS-polyacrylamide gel; the protein lysates were then electroblotted to a polyvinylidene difluoride membrane and blocked with phosphate buffered saline (PBS)-Tween (PBS-T; 50 mM potassium phosphate, pH 7.2, 150 mmol/L NaCl, and 0.5% Tween 20) with 5% nonfat dry milk powder for 1 hour. Blots were incubated overnight with a 1:1000 dilution of the primary antibody (anti-AGR3, 0.4 mg/mL) in 1Â PBS-T with 5% bovine serum albumin, and washed 3 times in PBS-T buffer, followed with the horseradish peroxidaseconjugated secondary antibody (1:1000; Amersham-GE Healthcare) diluted in PBS-T with nonfat dry milk powder for 1 hour at room temperature. Amersham ECL Plus Detection Reagent (GE Healthcare) was used to visualize the protein bands.
AGR3 Immunofluorescence Double Staining
Freshly cut frozen tissue specimens embedded in Tissue Tek Optimum Cutting Temperature Compound (Fisher Scientific) were fixed initially in 4% paraformaldehyde (Sigma-Aldrich). The samples were then permeabilized using 0.5% Triton X-100 for 15 minutes and blocked in 5% normal goat serum for 30 minutes. The first primary antibody, rabbit anti-AGR3 immunoglobulin G at a 1:200 dilution (initial concentration 0.4 mg/ mL), was incubated for 1.5 hours at room temperature, followed by incubation with the secondary antibody for 1 hour. Specimens were blocked again with 5% normal goat serum for 30 minutes and were then incubated with the second primary antibody, monoclonal mouse anti-b tubulin IV immunoglobulin G 1 at a 1:500 dilution (Sigma-Aldrich), at 41C overnight. The specimens were then incubated with the secondary antibody for 1 hour. The secondary antibodies used were Cy2-conjugated (green) AffiniPure Goat Anti-Mouse IgG, FCg Subclass 1 Specific, at a 1:200 dilution (Jackson ImmunoResearch 13 LG, and 24 HG tumors were identified by t test with 50 permutations to estimate false discovery rate (FDR) using dChip2009. A list of genes with median 2.2% FDR was identified. Unsupervised analysis using this set of genes was able to separate the SBOT/LG from HG. 
Statistical Analysis
Statistical analyses were carried out using the statistical package SPSS 15.0 for Windows (SPSS, Inc.). A nonparametric Mann-Whitney test was used to assess the statistical significance of the differences in AGR3 messenger RNA expression between normal HOSE cells and microdissected ovarian cancer tissues. P values<0.05 were considered to be statistically significant. The Kaplan-Meier method was used to generate survival curves for patients with high-staining and low-staining tissues, and staining intensity was correlated with survival time (in months) for both LG and HG SOCs. The Cox proportional hazards regression model was used to evaluate the relationship between survival time and staining intensity, International Federation of Gynecology and Obstetrics stage, and cytoreduction status.
RESULTS
Genes Upregulated in SBOTs/LG SOC Compared With HG SOC
In comparing the gene expression profiles of all ovarian tumors with those of the human ovarian surface epithelia, 1254 genes were found to be differentially expressed (P<0.005; Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/PAS/A76), which separated SBOT/LG from HG (Fig. 1) as determined by unsupervised clustering. In significance analysis of microarrays, 122 genes were found to be significantly upregulated in the SBOT/LG group compared with the HG group (Supplemental Table 2 , Supplemental Digital Content 2, http://links.lww.com/PAS/A77). The 20 most commonly upregulated genes are listed in Table 1 . Several of these genesFincluding DNAH9 5 , RSPHA4 3 , SNTN 10 , SPATA18 9 , TPPP3 30 , RSPH1 18 and TEKT1 11 Fare components of the cilium/flagellum or are involved in microtubule-based cellular movement. The overexpression of AGR3 in SBOTs and LG SOC samples was validated by RT-PCR as shown in Figure 2 . The relative expression of AGR3 in tumors was compared with that of the HOSE samples. AGR3 was significantly upregulated in SBOT and LG (P<0.001), but not in HG samples. Table 2 summarizes the immunostaining of AGR3 on the paraffin-embedded tissue sections. Representative stains of various sections are shown in Figure 3 . Epithelial cells from normal ovaries were negative for AGR3 (Fig. 3A) . All SBOT samples except 1 were positive for AGR3 with >50% of tumor cells staining (Fig. 3B) , whereas 20% of the LG samples stained. Moreover, in the majority of LG cases, <10% of the tumor cells exhibited staining (Fig. 3C) . HG SOC specimens also exhibited rare AGR3 staining (Fig. 3D ). We also stained 3 ovarian samples with ciliated epithelial inclusion cysts, 2 normal intestinal epithelial cells, and 3 normal fallopian tubes (Figs. 3E-H). All these samples were positive for AGR3 as well, with >50% of the epithelial cells exhibiting staining. Another 12 recurrent LG SOC samples from patients diagnosed initially with SBOTs were stained; all the initial SBOT samples stained, but loss of staining occurred with progression to LG SOC (Fig. 4) . Normal ovary (n = 4) 0 (0) 4 (100) SBOT (n = 16) 16 (94) 1 (6) SBOT with progression to LG serous ovarian carcinoma (n = 4) 4 (80) 1 (20) LG SOC (n = 56) 11 (20) 45 (80) HG SOC (n = 103) 20 (19) 83 (81) * LG tumor samples that were classified as negative had 0% to 9% tumor cells with AGR3-positive staining as Figure 4C . HG tumor samples that were classified as negative had no tumor cells with AGR3-positive staining. Tumor samples with 10% or more AGR3 positively stained tumor cells were deemed positive. AGR3 protein was detected mainly in SBOTs and LG SOC. In the Western blot analysis, all 5 SBOTs showed robust expression of AGR3 (19 kDa protein band), 2 of the 7 LG samples exhibited robust expression of AGR3, and none of the 6 HG samples expressed AGR3 (Fig. 5 ).
Immunohistochemistry of AGR3
AGR3 was expressed in ciliated cells. Double immunofluorescence staining of ciliated epithelial inclusion cysts and SBOT showed that AGR3 was expressed in ciliated cells. In ciliated epithelial inclusion cysts, only the ciliated cells expressed AGR3. Conversely, all tumor cells in the SBOTs were positive for both b-tubulin IV (a ciliaspecific protein marker) and AGR3 (Fig. 6 ). 8
AGR3 Expression was Correlated With Longer Survival Time
Survival analyses were carried out for patients with LG and HG serous carcinomas separately. The Kaplan-Meier curves (Figs. 7A, B ) indicated that AGR3-positive staining correlated significantly with better survival in patients within the LG group (P = 0.013) or the HG group (P = 0.008). The median survival time for patients with LG SOC was 72 months (range, 2 to 177 mo), compared with 39 months (range, 0 to 214 mo) for those with HG SOC. In the LG group (median age, 52 y; range, 23 to 85 y), 79% of patients had stage III disease and 18% of patients had stage IV disease at the time of diagnosis; 68% of patients underwent optimal cytoreductive surgery. In the HG group (median age, 61 y; range: 33 to 95 y), 93% of patients had stage III disease and 5% had stage IV disease at the time of diagnosis; 85% of patients underwent optimal cytoreductive surgery. Cox proportional hazards regression model analysis was further carried out to test the significance of AGR3 staining after being adjusted for age, stage, and debulking status. The Cox regression result showed that AGR3-positive staining was still a significant predictor of better survival for both the LG group (P = 0.029, HR = 3.42 with 95% CI, of 1.13-10.36) and the HG group (P = 0.021, HR = 1.86 with 95% CI, of 1.1-3.15).
DISCUSSION
In this study, we have identified a list of genes that are highly upregulated in SBOTs and LG SOCs, several of which are involved in cilia structure and/or microtubule-based cellular motility. It is generally accepted that cilia play a crucial role in normal development. Mice born lacking the cilia-encoding gene Kif3a die during The Anterior Gradient Homolog 3 embryogenesis, 15 and human ciliopathies lead to a range of defects as well. It is now becoming clear that ciliaFor rather the lack thereofFalso contribute to tumorigenesis. Wong et al 27 showed a loss of cilia during the development of basal cell carcinoma in mice and showed that this particular loss led to accelerated tumorigenesis. Although much remains unknown about their exact function and their role in various cancers, it is postulated that cilia may behave as tumor-suppressing organelles. In breast cancer cell lines, loss of primary cilia has been associated with tumor progression and the basal B subtype, which is analogous to triple-negative breast cancer. 29 Other studies have shown similar results; electron microscopy of ovarian tumors has shown tubal cells with numerous microvilli projecting into the lumen and the presence of ciliated cells in both benign and borderline tumors, but not in malignant tumors. 22 Our coimmunofluorescent staining showed similar results, with AGR3 being highly expressed in the ciliated cells of epithelial inclusion cysts and SBOTs.
AGR3 has been described as a membrane protein in breast cancer cells, and may have a role in tumorigenesis by interacting with metastasis-associated genes. 4 The overexpression of AGR3 in SBOTs was also validated in our study using Gilks' microarray data, 6 which are available at the Oncomine website. 16 In our study, the overexpression of AGR3 in borderline serous tumors and LG SOCs was further confirmed by RT-PCR, Western blotting, and immunostaining. These findings are consistent with the pathologic observation that SBOTs and LG SOCs are well-differentiated tumors compared with HG SOCs, and further support the use of a 2-tiered grading system.
In our study, we also found that AGR3 staining correlated with the level of tumor differentiation. A similar percentage of HG and LG cells stained for AGR3, which is likely attributable to our initial selection of the HG SOC subset according to survival extremes, with a disproportionate number of longer surviving individuals in the HG group relative to those individuals randomly selected in the LG group. Thus, a higher than expected number of stained slides was observed in the HG SOC group.
Similar results were obtained with 12 recurrent LG SOC samples from patients who were initially diagnosed with SBOTs, suggesting that during the progression of SBOT to LG SOCs, the number of AGR3-positive cells decreases. As many of the overexpressed genes in SBOTs and LG SOC are involved in the cilia structure, the decrease in ciliated cells in LG SOCs may suggest that the progression of SBOTs to LG SOCs involves the dedifferentiation or loss of ciliated structures. Therefore, AGR3 may serve as a differentiation factor, and the loss of AGR3 is associated with progression of SBOTs. It is interesting that we also established a correlation between survival and the percentage of AGR3 positively stained tumor cells in tumor samples. Although uncommon in the LG and HG SOC subtypes, 17 those patients with tumors expressing AGR3 survived significantly longer than those without AGR3 positively stained tumor cells. AGR3 thus may be a biomarker for SBOTs, and may indicate a better prognosis in patients who are newly diagnosed with ovarian cancer.
In conclusion, our findings support the concept that SBOTs and LG SOC form a continuum, whereas HG SOCs arise from a clinically and pathologically distinct entity. Moreover, our data suggests that AGR3 serves as a marker of tumor differentiation, leads to more favorable prognosis and longer survival, and is present in ciliated cells. These findings warrant further investigation into the role of cilia in tumorigenesis and the use of AGR3 as a biomarker and a potential therapeutic target.
